2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. CDK

CDK

Cyclin dependent kinase

CDK

Related Products

PDF 1.19 MB

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.

There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.

CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

CDK Isoform Specific Products:

CDK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-47026
    Protein kinase inhibitor 6
    		Inhibitor 99.04%
    Protein kinase inhibitor 6 is a protein kinase inhibitor.
    Protein kinase inhibitor 6
  • HY-148868A
    Akt1&PKA-IN-2
    		Inhibitor
    Akt1&PKA-IN-2 ((R)-29) is an inhibitor of PKB/AKT with cyclin-dependent kinase 2 (CDK2) selectivity. Akt1&PKA-IN-2 inhibits AKT1, PKAa and CDK2a with IC50 values of 0.007 µM, 0.01 µM and 0.69 µM, respectively.
    Akt1&PKA-IN-2
  • HY-149819
    CDK/HDAC-IN-3
    		Inhibitor 99.60%
    CDK/HDAC-IN-3 is an orally active HDACs/CDKs dual inhibitor. CDK/HDAC-IN-3 has potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2 and HDAC3 with IC50 values of 98.32 nM, 98.85 nM, 100 nM, 62.12 nM, 93.28nM and 82.87 nM. CDK/HDAC-IN-3 can be used for the acute myeloid leukemia (AML) .
    CDK/HDAC-IN-3
  • HY-N2423
    Sinigrin hydrate
    		Inhibitor 99.77%
    Sinigrin (Allyl-glucosinolate) hydrate is an orally active glucosinolate found in cruciferous plants. Sinigrin hydrate possesses multiple activities such as anti-cancer, antibacterial, antifungal, anti-inflammatory, antioxidant, and inhibition of fat synthesis. Sinigrin hydrate can be used in the research of tumors, inflammatory, and metabolic diseases.
    Sinigrin hydrate
  • HY-115992
    CDK4/6-IN-9
    		Inhibitor
    CDK4/6-IN-9 (compound 10) is a selective CDK4/6 inhibitor with an IC50 of 905 nM for CDK6/cyclin D1. CDK4/6-IN-9 has the potential for multiple myeloma (MM) research.
    CDK4/6-IN-9
  • HY-117025
    Manzamine A
    		Inhibitor 98.2%
    Manzamine A, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and CDK-5 with IC50s of 10.2 μM and 1.5 μM, respectively. Manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A has antimalarial and anticancer activities. Manzamine A also shows potent activity against HSV-1.
    Manzamine A
  • HY-111388
    SEL120-34A
    		Inhibitor
    SEL120-34A is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
    SEL120-34A
  • HY-119966
    CCT036477
    		Inhibitor 99.42%
    CCT036477 is a Wnt/β-catenin pathway inhibitor. CCT036477 blocks transcription at β-catenin without altering its levels. CCT036477 inhibits proliferation of various cancer cells, development of embryos, and expression of Wnt target genes (PPARδ, Cyclin D1, TCF4, and ID2).
    CCT036477
  • HY-RS02372
    Cdk19 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Cdk19 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk19 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Cdk19 Mouse Pre-designed siRNA Set A
    Cdk19 Mouse Pre-designed siRNA Set A
  • HY-120942
    XIE18-6
    		Inhibitor 98.98%
    XIE18-6 is a potent INK4C (p18) inhibitor. XIE18-6 shows potent bioactivity in hematopoietic stem cells (HSCs) expansion with an ED50 of 105.5 nM.
    XIE18-6
  • HY-168162
    ZLC491
    		Degrader
    ZLC491 is an orally active CDK12/13 PROTAC degrader. ZLC491 can be used in anticancer research.
    ZLC491
  • HY-129336S
    Abemaciclib metabolite M20-d8
    		Inhibitor 99.26%
    Abemaciclib metabolite M20-d8 is the deuterium labeled Abemaciclib metabolite M20. Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor.
    Abemaciclib metabolite M20-d<sub>8</sub>
  • HY-173523
    KI-CDK9d-32
    		Degrader
    KI-CDK9d-32 is a CDK9 PROTAC degrader (DC50: 0.89 nM). KI-CDK9d-32 promotes the ubiquitination and degradation of CDK9. KI-CDK9d-32 inhibits the MYC pathway and disrupts nucleolar homeostasis. KI-CDK9d-32 has anticancer activity. (Pink: CDK9 ligand (HY-153718); Blue: E3 ligase CRBN ligand (HY-163233); Black: Linker (HY-W011657); E3 ligase CRBN ligand-linker conjugate (HY-173525)).
    KI-CDK9d-32
  • HY-168996
    LA-CB1
    		Degrader
    LA-CB1 is an Abemaciclib (HY-16297A) derivative that targets CDK4/6 and promotes its degradation via the ubiquitin-proteasome pathway, thereby disrupting the CDK4/6-Cyclin D1-Rb-E2F axis and inducing G0/G1 cell cycle arrest and apoptosis. LA-CB1 exhibits antiproliferative activity against MDA-MB-231 cells, with an IC50 of 0.27 µM, and effectively inhibits epithelial-mesenchymal transition (EMT), cell migration, invasion, and angiogenesis. In highly aggressive models such as triple-negative breast cancer (TNBC), LA-CB1 significantly suppresses tumor growth in a dose-dependent manner. LA-CB1 holds potential for research in the field of breast cancer.
    LA-CB1
  • HY-122665A
    HTH-01-091 TFA
    		Inhibitor 99.48%
    HTH-01-091 TFA is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM. HTH-01-091 TFA also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 TFA can be uesd for breast cancer research.
    HTH-01-091 TFA
  • HY-RS02348
    CDK1 Human Pre-designed siRNA Set A
    		Inhibitor

    CDK1 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    CDK1 Human Pre-designed siRNA Set A
    CDK1 Human Pre-designed siRNA Set A
  • HY-111463
    CDK8-IN-3
    		Inhibitor 99.21%
    CDK8-IN-3 is an inhibitor of CDK8 extracted from patent WO2016041618A1, compound example 1.7.
    CDK8-IN-3
  • HY-RS02374
    CDK2 Human Pre-designed siRNA Set A
    		Inhibitor

    CDK2 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    CDK2 Human Pre-designed siRNA Set A
    CDK2 Human Pre-designed siRNA Set A
  • HY-123535
    P18IN003
    		Inhibitor 99.49%
    P18IN003 is a potent p18(INK4C) inhibitor andspecifically block the activity of p18 protein. P18IN003 has the potential to be aneffective chemical agent for therapeutic expansion of HSC.
    P18IN003
  • HY-15777R
    Ribociclib (Standard)
    		Inhibitor
    Ribociclib (Standard) is the analytical standard of Ribociclib. This product is intended for research and analytical applications. Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.
    Ribociclib (Standard)
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
CDK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.